Endo, Novartis begin Voltaren gel licensing deal
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.